Supplementary key words heart cells • mitochondria • phospholipids • glycerol kinase • 1,2-diacyl-sn -glycerol acyltransferase • phosphatidate phosphohydrolase Cardiolipin (CL) is a major membrane phospholipid in most mammalian cells and is localized primarily to the inner mitochondrial membrane where it comprises approximately 20% of the mitochondrial phospholipid mass (1) (2) (3) . In addition, CL has been identified in the outer mitochondrial membrane (4, 5) . CL was shown to be required for the reconstituted activity of a number of key mammalian mitochondrial enzymes involved in cellular energy metabolism (6) (7) (8) (9) (10) (11) (12) (13) (14) . More recently, peroxidation of CL in mitochondria of rat basophile leukemia cells resulted in dissociation of cytochrome c from mitochondrial inner membranes, an initial step in cytochrome c-mediated apoptosis (15) . In mammalian tissues, CL contains four fatty acid side chains occupied primarily by unsaturated fatty acids of 16-18 carbons in length (16) . The fatty acyl species appeared to be the important structural requirement for the high protein binding affinity of CL (17) . Dietary modification of the fatty acyl species composition of CL was shown to alter the oxygen consumption in cardiac mitochondria (18, 19) . The specific activity of cytochrome c oxidase reconstituted with CL varied markedly and significantly with different molecular species of the phospholipid. Thus, the appropriate fatty acyl composition of CL is important for optimum mitochondrial respiratory activity.
CL de novo biosynthesis begins with the conversion of phosphatidic acid (PtdOH) to cytidine-5 Ј -diphosphate-1,2-diacyl-sn -glycerol (CDP-DG) catalyzed by PtdOH:CTP cytidylyltransferase (EC 2.7.7.41) (20) . CDP-DG is then condensed with sn -glycerol-3-phosphate to form phosphatidylglycerol (PtdGro) phosphate catalyzed by PtdGro phosphate synthase (EC 2.7.8.5). The PtdGro phosphate is immediately converted to PtdGro by a highly active PtdGro phosphate phosphatase (EC 3. 1.3.27) . Finally, PtdGro is con-densed with another molecule of CDP-DG to form CL catalyzed by CL synthase (21) . The de novo CL biosynthetic enzymes lack fatty acyl species specificity (22, 23) . Thus, like other phospholipids, newly synthesized CL must be rapidly remodeled by a deacylation-reacylation pathway to obtain fatty acyl groups (24) . The enzyme responsible for CL deacylation in the mitochondria is phospholipase A 2 (25) (26) (27) . We have characterized the activity of monolysocardiolipin acyltransferase (MLCL AT) specific for the acylation of MLCL to CL in the heart and mammalian tissues (28) .
Recent studies support the hypothesis of functionally independent acyl-CoA pools within mammalian cells that may be channeled toward specific fates rather than being freely available for all possible enzymatic reactions (29) (30) (31) (32) . Etomoxir is a member of the oxirane carboxylic acid carnitine palmitoyl transferase I inhibitors and has been suggested as a therapeutic agent for the treatment of heart failure (33) (34) (35) . Acute etomoxir treatment irreversibly inhibits the activity of carnitine palmitoyltransferase I. As a result, fatty acid import into the mitochondria and ␤ -oxidation is reduced, whereas cytosolic fatty acid accumulates and glucose oxidation is elevated. Prolonged incubation (24 h) with etomoxir produces diverse effects on the expression of several metabolic enzymes (36) . It had been postulated that acute etomoxir treatment might stimulate de novo phospholipid biosynthesis in the mammalian heart (37). However, this had never been demonstrated. In this study, we examined if acute etomoxir treatment of H9c2 cardiac myoblast cells indeed stimulated de novo CL and phospholipid biosynthesis, and if etomoxir mediated distinct metabolic channeling of fatty acid and glycerol into CL. Our results indicate that etomoxir treatment of H9c2 cardiac myoblast cells produces a diverse plethora of effects on overall de novo glycerolipid biosynthesis from various metabolic precursors. In addition, etomoxir produces a distinct and differential metabolic channeling of glycerol and fatty acid precursors into CL in H9c2 cells. Rat heart H9c2 myoblastic cells were incubated in DMEM containing 10% fetal bovine serum until near confluence. In some experiments, cells were preincubated for 2 h with DMEM (serumfree) in the absence or presence of 1-80 M etomoxir and then incubated for 2 h with 0. (10 Ci/dish). The medium was removed and the cells washed twice with ice-cold saline and then harvested from the dish with 2 ml methanol-water (1:1, v/v) for lipid extraction. An aliquot of the homogenate was taken for the determination of total uptake of radioactivity into cells. Phospholipids were then isolated and radioactivity in these determined as previously described (38) .
MATERIALS AND METHODS
For enzyme studies, H9c2 cells were washed twice with ice-cold saline and harvested with 2 ml homogenization buffer (10 mM Tris-HCL, pH 7.4, 0.25 M sucrose). The cells were homogenized with 15 strokes of a Dounce A homogenizer. The homogenate was centrifuged at 1,000 g for 5 min. The resulting supernatant was centrifuged at 10,000 g for 15 min. The resulting pellet was resuspended in 1 ml of homogenizing buffer and designated the mitochondrial fraction. The resulting supernatant was centrifuged at 100,000 g for 60 min to obtain the cytosolic fraction. The resulting pellet from this centrifugation was resuspended in 1 ml of homogenizing buffer and designated the microsomal fraction. Glycerol kinase in cytosol was determined by measuring the conversion of [1, H]glycerol to [1, H]glycerol-3-phosphate as described (40 (28) . Mitochondrial and microsomal sn -glycerol-3-phosphate acyltransferase (GPAT) activities were determined as described (42) . Microsomal 1,2-diacyl-sn -glycerol acyltransferase (DGAT) activity was determined as described (43) . Total cell and membrane phosphatidate phosphohydrolase (PAP) activity was determined as described (44) . In some experiments microsomal DGAT and cytosolic glycerol kinase activities were determined in the absence or presence of 30 M etomoxiryl-CoA. The fatty acid composition of CL in H9c2 cells was determined as described (45) . Phospholipid phosphorus was determined as described (46) . Protein was determined as described (47) , and Student's t -test was used for statistical analysis. The level of significance was defined as P Ͻ 0.05.
RESULTS

Etomoxir reduces CL biosynthesis from fatty acids
Fatty acid import into mitochondria and its subsequent ␤ -oxidation is mediated by carnitine palmitoyltransferase at PENN STATE UNIVERSITY, on February 21, 2013 www.jlr.org Downloaded from I and II (48) . Etomoxir, 2-[6-(4-chlorophenoxy)hexyl] oxirane-2-carboxylate, is a compound known to inhibit ␤ -oxidation in mitochondria by irreversibly inhibiting carnitine palmitoyltransferase I activity (33) . It was postulated that etomoxir stimulated phospholipid biosynthesis in mammalian heart (37) . However, the effect of etomoxir on the biosynthesis of CL, a phospholipid exclusively found in mitochondria, had not been investigated. We chose H9c2 cardiac myoblast cells since it is a cell line derived from embryonic rat heart and these cells readily take up radiolabeled glycerol and fatty acids and incorporate them into CL (38) . H9c2 cells were preincubated with 1-80 M etomoxir for 2 h and incubated with 0.1 mM [1-14 C]oleic acid bound to albumin (1:1 molar ratio) for 2 h, and radioactivity incorporated into CL determined. These concentrations of etomoxir have been used in various cell culture models to inhibit carnitine palmitoyltransferase I activity (49, 50) . Oleic acid (C18:1) was chosen for these experiments since this is the major unsaturated fatty acid found in CL in H9c2 cells ( Table 1 ). The 2 h treatment was chosen to avoid the complicated effects of altered gene expression seen during prolonged incubation (24 h) with this compound (36) . In H9c2 cells, CL was ( Table 2 ). In contrast, radioactivity incorporated into PtdOH was unaltered. Radioactivity incorporated into CDP-DG was low, twice background (data not shown). Total radioactivity associated with the cells was unaltered by etomoxir treatment. Thus, etomoxir treatment reduced [1-14 C]oleic acid incorporation into PtdGro and CL.
The mechanism for the reduction in [1-14 C]oleic acid incorporation into PtdGro and CL was examined. The phospholipid phosphorus concentration of these cells was 124 Ϯ 14 nmol/mg protein and was unaltered by pretreatment with etomoxir for 2 h. The percent phospholipid phosphorus of CL in these cells was 4.2% and was unaltered by pretreatment with etomoxir for 2 h. Since [1-14 C]oleic acid incorporated into PtdOH was unaltered, we examined if the reduction in [1-14 C]oleic acid incorporated into PtdGro and CL was due to a reduction in the activities of the enzymes of the CDP-DG pathway of CL biosynthesis. Cells were incubated for 2 h in the absence or presence of 40 M etomoxir. The cells were homogenized, mitochondrial fractions prepared, and the activities of the biosynthetic enzymes determined. As seen in Table  3 , etomoxir did not affect mitochondrial PtdOH:CTP cytidylyltransferase, PtdGro phosphate synthase/phosphatase, or CL synthase activities. Thus, the reduction in [1- H9c2 cells were incubated for 2 h in the absence or presence of 40 M etomoxir. Cardiolipin (CL) was isolated and the percent fatty acid composition of CL determined. Results represent the mean of two experiments. 14 C]oleic acid incorporation into PtdGro and CL was not due to alterations in the activities of the enzymes of de novo CL biosynthesis. Unsaturated fatty acids enter into phospholipids mainly by deacylation-reacylation pathways (51) . Since [1-14 C]oleic acid incorporation into PtdGro and CL were reduced to a similar extent and PtdGro is the immediate precursor to CL, it was possible that the reduction in radioactivity incorporated into CL was due to a either a reduction in the specific radioactivity of its immediate precursor, PtdGro, or a reduction in CL remodeling. To test this hypothesis, cells were preincubated with 40 M etomoxir for 2 h then incubated with [1-14 C]palmitic acid for 2 h and radioactivity incorporated into lipids determined. In rat heart, palmitic acid enters CL mainly by de novo biosynthesis (28) . As seen in Table 4 , incubation of cells with 40 M etomoxir caused a 46% (P Ͻ 0.05), 24% (P Ͻ 0.05), and 37% (P Ͻ 0.05) reduction in [1-14 C]palmitic acid incorporated into CL, PtdGro, and phosphatidylinositol (PtdIns), respectively, compared with controls. In contrast, radioactivity incorporated into phosphatidylethanolamine (PtdEtn), phosphatidylcholine (PtdCho), and phosphatidylserine (PtdSer) were elevated 52% (P Ͻ 0.05), 21% (P Ͻ 0.05), and 3.8-fold (P Ͻ 0.05), respectively, in etomoxir-treated cells compared with controls. Radioactivity incorporated into CDP-DG was low, twice background (data not shown). [1-14 C]palmitic acid incorporated into DG was increased 93% (P Ͻ 0.05), and incorporation into 1,2,3-triacyl-sn-glycerol (TG) decreased 55% (P Ͻ 0.05) in etomoxir-treated cells compared with control. Total radioactivity associated with the cells was unaltered by etomoxir treatment. We next examined if etomoxir affected mitochondrial PLA 2 and MLCL AT activities, the CL remodeling enzymes. H9c2 cells were incubated with 40 M etomoxir for 2 h. The cells were homogenized, mitochondrial fractions prepared, and these enzyme activities determined. Etomoxir treatment did not affect MLCL AT and PLA 2 activities (Table 3) . Thus, the reduction in [1-14 C]fatty acid incorporation into CL was due to the reduction in radioactivity of its immediate precursor, PtdGro, and not due to alterations in CL remodeling. In addition, etomoxir treatment stimulated [1-14 C]palmitic acid incorporation into PtdCho, PtdEtn, PtdSer, and DG and reduced [1-14 C]palmitic acid incorporation into TG (Table 4) .
PtdCho and PtdEtn de novo biosynthesis utilizes DG, and PtdSer de novo biosynthesis utilizes PtdEtn and PtdCho as PtdOH precursors. Since [1-14 C]palmitic acid incorporated into DG was elevated, and [1-14 C]palmitic acid incorporated into CL, PtdGro, and PtdIns reduced, it was possible that etomoxir treatment stimulated microsomal GPAT activity or resulted in a re-direction of phospholipid biosynthesis away from CDP-DG-utilizing reactions toward DG-utilizing reactions. Cells were incubated plus or minus 40 M etomoxir for 2 h, then microsomal and mitochondrial GPAT activities determined. Microsomal and mitochondrial GPAT activities were unaltered in cells treated with etomoxir (Table 3) . PAP lies at a branch point in glycerolipid biosynthesis and controls the direction of PtdOH utilization (51) . Cells were preincubated plus or minus 40 M etomoxir for 2 h, then total and membrane PAP activity determined. Total cellular PAP activity was 0.65 Ϯ 0.10 mU/total units lactate dehydrogenase and was unaltered by etomoxir treatment (average of five experiments). In contrast, membrane PAP was increased 35% (P Ͻ 0.05) in etomoxir-treated cells compared with control. Membrane PAP activity was 0.13 Ϯ 0.01 mU/total units lactate dehydrogenase and was unaltered by 40 M etomoxiryl-CoA treatment (average of three experiments). Since treatment of membranes directly with etomoxiryl-CoA did not affect in vitro PAP activity, it is concluded that the increase in membrane PAP activity seen in cells treated with etomoxir was caused by the elevation in cytosolic fatty acid produced by the etomoxir-mediated inhibition of mitochondrial ␤-oxidation. Thus, the reduction in fatty acid incorporation into CL, PtdGro, and PtdIns in etomoxirtreated cells was due to a re-direction of glycerolipid biosynthesis away from CDP-DG-utilizing reactions toward DG-utilizing reactions. Surprisingly, etomoxir reduced [1-14 C]palmitic acid incorporation into TG. We examined if etomoxir altered DGAT activity. H9c2 cells were incubated with 40 M etomoxir for 2 h. The cells were then homogenized and microsomal fractions prepared and DGAT activities determined. DGAT activity was reduced 81% (P Ͻ 0.05) in etomoxir-treated cells compared with controls (Table 3 ). The mechanism of the etomoxir-mediated inhibition of DGAT activity was determined. Microsomal membranes from H9c2 cells were prepared and DGAT activity determined in the absence or presence of 40 M etomoxirylCoA. DGAT activity was 94 Ϯ 15 pmole/min·mg protein in control membranes and was reduced 67% (P Ͻ 0.05) to 31 Ϯ 2 pmole/min·mg protein in membranes incubated with etomoxiryl-CoA. Since [1-14 C]palmitic acid incorporation into DG was elevated and DGAT activity reduced, we conclude that the reduction in [1-14 C]palmitic acid incorporation into TG was due to a decrease in flux of fatty acids toward TG biosynthesis mediated by an inhibition in DGAT activity.
Etomoxir treatment produces diverse effects on de novo phospholipid biosynthesis from head group precursors in H9c2 cells
Since etomoxir inhibited CL formation from exogenous fatty acid in H9c2 cells, we anticipated that etomoxir would also reduce CL biosynthesis from the glycerol head group precursor. To examine if etomoxir treatment altered de novo CL biosynthesis from glycerol, H9c2 cardiac myoblast cells were preincubated for 2 h in the absence or presence of 40 M etomoxir and then incubated with 0.1 M [1,3-3 H]glycerol for 2 h, and radioactivity incorporated into CL and intermediates of the CDP-DG pathway of CL biosynthesis was determined. Surprisingly, incubation of cells with etomoxir resulted in 67% (P Ͻ 0.05), 48% (P Ͻ 0.05), and 50% (P Ͻ 0.05) increase in [1, H]glycerol incorporation into CL, PtdGro, and PtdOH, respectively, compared with controls ( Table 5) . Radioactivity incorporated into CDP-DG was twice background (data not shown). Total uptake of [1, H]glycerol in H9c2 cells was unaltered by the presence of etomoxir. Since the specific activity of the radioactive glycerol may have been diluted by the intracellular glycerol concentration, the experiment was repeated with 0.1 mM [1, H]glycerol in the medium. The use of 0.1 mM glycerol is representative of plasma glycerol concentrations (53) . Similar to the results with 0.1 M glycerol, CL, PtdGro, and PtdOH biosynthesis were elevated and total uptake of [1, H]glycerol was unaltered by etomoxir treatment in these experiments (Table 5) . Thus, etomoxir treatment of H9c2 cells apparently enhanced de novo CL biosynthesis from [1, 
We examined the mechanism for the etomoxir-mediated increase in glycerol incorporation into CL. Since glycerol kinase is the rate-limiting step in muscle cell glycerol metabolism (54), we examined if glycerol kinase activity was elevated in these cells. Cells were incubated for 2 h in the absence or presence of 40 M etomoxir, and cytosol prepared and glycerol kinase activity determined. Glycerol kinase activity was elevated 33% (P Ͻ 0.05) in etomoxir-treated cells compared with control (Table 3 ). The mechanism for the etomoxir-mediated elevation in glycerol kinase activity was determined. Cytosolic fractions were prepared from H9c2 cells and glycerol kinase activity was determined in the absence or presence of 40 M etomoxiryl-CoA. The presence of etomoxiryl-CoA in the incubation mixture stimulated glycerol kinase in vitro activity 67% (P Ͻ 0.05) from 0.9 Ϯ 0.2 to 1.6 Ϯ 0.1 nmol/min · mg protein. Since the activities of the de novo CL biosynthetic enzymes, GPAT activities, and glycerol uptake were unaltered, the elevation in radioactivity incorporated into CL in etomoxir treated cells was due to an increase in glycerol flux through the CDP-DG pathway mediated by an increase in glycerol kinase activity.
Since [1, H]glycerol incorporation into PtdOH was increased by etomoxir treatment, we examined if incorporation into other glycerolipids was altered. As seen in Table 5, radioactivity incorporated into PtdIns, PtdSer, PtdCho, and PtdEtn was elevated 50% (P Ͻ 0.05), 50% (P Ͻ 0.05), 2.5-fold (P Ͻ 0.05), and 2.7-fold (P Ͻ 0.05), respectively, in etomoxir-treated cells compared with controls, indicating an elevation in biosynthesis of these lipids from [1, H]glycerol, which would be expected if glycerol kinase activity was elevated. In contrast, incorporation of [1, H]glycerol into DG and TG was reduced 33% (P Ͻ 0.05) and 80% (P Ͻ 0.05), respectively, compared with controls. Since DGAT activity was reduced in etomoxirtreated cells (Table 3) , we interpret this data to indicate that [1, Table 7) . Total uptake of inositol was reduced 26% (P Ͻ 0.05) in etomoxirtreated cells compared with controls, which would explain why incorporation of myo-[ 3 H]inositol into PtdIns was reduced. Total uptake of [ 3 H]serine into cells was unaltered by etomoxir. Treatment of cells with etomoxir resulted in a 22% (P Ͻ 0.05) decrease in radioactivity incorporated into PtdSer compared with controls. In contrast, etomoxir treatment resulted in a 47% (P Ͻ 0.05) increase in radioactivity incorporated into PtdEtn compared with controls. The reduction in radioactivity incorporated into PtdSer was quantitatively accounted for by the elevation in PtdEtn, suggesting that etomoxir stimulated PtdEtn synthesis from PtdSer. Thus, etomoxir inhibited de novo PtdIns biosynthesis and stimulated PtdEtn biosynthesis from PtdSer. Taken together, the above results clearly indicate that etomoxir treatment has diverse effects on de novo phospholipid biosynthesis from various metabolic precursors. In addition, etomoxir mediates a distinct and differential metabolic channeling of glycerol and fatty acid precursors into CL.
DISCUSSION
The objective of this study was to examine if etomoxir treatment stimulated CL biosynthesis in H9c2 cells and if etomoxir mediated metabolic channeling of fatty acid and glycerol precursors into CL. Our results indicate that etomoxir treatment of H9c2 cardiac myoblast cells produces a diverse plethora of effects on overall de novo glycerolipid biosynthesis from various metabolic precursors. In addition, etomoxir produces a distinct and differential metabolic channeling of glycerol and fatty acid precursors into CL in H9c2 cardiac myoblast cells.
The final steps of de novo CL biosynthesis have been shown to occur on the inner side of the inner mitochondrial membrane (55) . Etomoxir is taken up by cells and rapidly converted to etomoxiryl-CoA, a potent inhibitor of mitochondrial fatty acid import and ␤-oxidation. The result is an accumulation of extramitochondrial fatty acid and an elevation in glucose oxidation. Treatment of H9c2 cells with etomoxir reduced the incorporation of [1-14 C]fatty acids into CL and PtdGro in H9c2 cardiac myoblast cells but did not affect total incorporation of radioactivity into these cells. In addition, the activities of the enzymes of the CDP-DG pathway of CL biosynthesis were unaltered by etomoxir treatment. These results indicated that the reduction in fatty acid incorporation into CL was not due to a reduction in [1-14 C]fatty acid uptake or a decrease in the de novo CL biosynthetic enzymes. In contrast, incorporation of [1-14 C]fatty acid into PtdCho and PtdEtn were elevated in etomoxir-treated cells. Finally, radioactive fatty acid incorporation into PtdIns was reduced by etomoxir treatment. These results initially indicated that etomoxir treatment mediated a redirection of phospholipid biosynthesis from fatty acid precursors away from CDP-DG-utilizing pathways and toward DG-utilizing pathways. Recent studies have indicated that there may be selectivity of fatty acyl-CoA pools for various glycerolipid biosynthetic pathways (29) (30) (31) (32) ). In the current study, the redirection in fatty acyl-CoA selectivity for lipid synthesis was mediated by an increase in membrane PAP activity in etomoxir-treated cells. However, in vitro PAP activity was unaltered in membranes incubated directly with etomoxiryl-CoA. Incubation of cells with etomoxir will produce an elevation in extramitochondrial fatty acid, and increase in extramitochondrial fatty acid should activate membrane PAP activity in vivo (52) . Thus, the mechanism for the etomoxir-mediated reduction in fatty acid incorporation into PtdGro and CL appeared to be a decrease in fatty acid flux through the CDP-DG pathway. C]palmitic acid incorporated into PtdSer observed in the presence of etomoxir was likely due to an increase in the specific radioactivity of its immediate precursors, PtdEtn and PtdCho. Elevated phospholipid synthesis by etomoxir-induced inhibition of mitochondrial ␤-oxidation had been postulated (37) , but until the current study had not been directly demonstrated. A previous study showed that incubation of murine hematopoietic cell lines with etomoxir stimulated sphingolipid synthesis (56) . We observed elevated [methyl-3 H]choline incorporation into SM in H9c2 cells incubated with etomoxir consistent with an etomoxir-mediated elevation in sphingolipid synthesis. Surprisingly, etomoxir treatment reduced [1-14 C]palmitic acid incorporation into TG. DGAT activity was markedly reduced in these cells and etomoxiryl-CoA inhibited DGAT in vitro activity. These data suggested that the etomoxir-mediated reduction in fatty acid incorporation into TG was due to a preferential channeling of DG for glycerophospholipid synthesis over TG synthesis and support the hypothesis of selectivity of acute regulation of fatty acyl-CoA pools for various glycerolipid biosynthetic pathways (57) .
The de novo enzymes for CL biosynthesis show little acyl group specificity (22, 23) , and MLCL AT activity may be rate-limiting for the molecular remodeling of CL (58). Thus, it was possible that the reduction in [1-14 C]oleic acid incorporation into CL was due to a reduced availability of intramitochondrial fatty acid for CL remodeling or to alteration in the activity of the CL remodeling enzymes. Palmitic acid enters into rat heart CL mainly by the de novo biosynthetic pathway (28) . Since a similar reduction in radioactivity incorporation into CL was seen with both [1-14 C]palmitic acid and [1-14 C]oleic acid, and the activities of the CL remodeling enzymes in mitochondrial fractions were unaltered in etomoxir-treated cells, it can be concluded that the reduction in [1-14 C]fatty acid incorporation into CL was not due to a reduced availability of intra-mitochondrial fatty acid for CL remodeling. In support of this was the observation that the reduction in [1-14 C]fatty acid incorporation into PtdGro, the immediate precursor of CL, was similar to that of CL in etomoxirtreated cells. In addition, mitochondrial GPAT activity was unaltered by etomoxir treatment. A previous study on the topography of PtdOH synthesis in rat liver mitochondria had indicated that lysoPtdOH and PtdOH are formed from sn-glycerol-3-phosphate and palmitoyl-CoA on the outer surface of the mitochondrial outer membrane and that this is followed by movement of PtdOH to the inner membrane for PtdGro and CL biosynthesis (59) .
We expected to see a reduction in [1, H]glycerol head group incorporation into CL in cells treated with etomoxir since [1-14 C]fatty acid incorporation into CL was reduced and the activities of the enzymes of the CDP-DG pathway of CL biosynthesis were unaltered. Surprisingly, the opposite was observed. Treatment of cells with etomoxir resulted in an increase in [1, H]glycerol incorporation into CL and other glycerophospholipids. Since total [1, H]glycerol incorporation into cells was unaltered, these data indicated that etomoxir treatment mediated metabolic channeling of glycerol into CL and other glycerophospholipids. A recent study had implicated glycerol kinase as a rate-limiting step in muscle cell glycerol metabolism (54) . We observed an increase in glycerol kinase activity in etomoxir-treated cells and etomoxiryl-CoA stimulated glycerol kinase in vitro activity. The increase in glycerol kinase activity in etomoxir-treated cells would explain the elevation in [1, H]glycerol incorporation into CL and other glycerophospholipids since GPAT activities were unaltered. [1, H]glycerol incorporation into TG was reduced by etomxoir treatment, indicating channeling of glycerol away from TG biosynthesis. The large reduction in DGAT activity observed in etomoxir-treated cells was likely responsible for the reduction in TG synthesis from glycerol. Surprisingly, [1, H]glycerol incorporation into DG was reduced in extomoxir-treated cells. These data indicate the existence of separate pools of DG available for glycerolipid synthesis in H9c2 cells: a pool that may be rapidly utilized for glycerophospholipid synthesis and a pool utilized for general glycerolipid synthesis.
Surprisingly, etomoxir did not affect all de novo phospholipid biosynthesis from head group precursors in an identical manner. PtdIns de novo biosynthesis from myoinositol was markedly inhibited in H9c2 cells in the presence of etomoxir. The mechanism was an etomoxir-mediated reduction in uptake of myo-inositol. Uptake of serine was unaltered in H9c2 cells treated with etomoxir, and PtdEtn biosynthesis from serine was elevated. At first glance it appeared that PtdSer biosynthesis from serine was reduced in etomoxir-treated cells. However, PtdEtn is synthesized from PtdSer by PtdSer decarboxylase in the mitochondria (60) . Since the combined amount of radioat PENN STATE UNIVERSITY, on February 21, 2013 www.jlr.org Downloaded from
